Teratoma screening: Difference between revisions

	Teratoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Teratoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Staging
Laboratory Findings
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Teratoma screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Teratoma screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Teratoma screening
CDC on Teratoma screening
Teratoma screening in the news
Blogs on Teratoma screening
Directions to Hospitals Treating Teratoma
Risk calculators and risk factors for Teratoma screening

Revision as of 20:11, 25 October 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gertrude Djouka, M.D.[2]

There is insufficient evidence to recommend routine screening for [disease/malignancy].

There is insufficient evidence to recommend routine screening for Teratoma.

@@ Line 1: / Line 1: @@
 __NOTOC__
 {{Teratoma}}
-{{CMG}}; {{AE}}   {{mbt}}
+{{CMG}}; {{AE}}   {{G.D.}}
 ==Overview==
 There is insufficient evidence to recommend routine screening for [disease/malignancy].
-OR
-According to the [guideline name], screening for [disease name] is not recommended.
-OR
-According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
 ==Screening==
 There is insufficient evidence to recommend routine screening for Teratoma.
-Based on fair evidence, screening for testicular cancer would not result in an appreciable decrease in mortality, in part because therapy at each stage is so effective.
-screening  would result in unnecessary diagnostic procedures with attendant morbidity.<ref name="urlTesticular Cancer Screening (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf">{{cite web |url=https://www.ncbi.nlm.nih.gov/books/NBK65967/ |title=Testicular Cancer Screening (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf |format= |work= |accessdate=}}</ref>
 ==References==